Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2/3 × OTHER × abiraterone × Clear all

Phase

Phase 2 28 Phase 1 5 Phase NA 4 Phase 1/2 3 Phase 3 2 Phase EARLY_PHASE1 1 Phase 2/3 1

Status

Sponsor Class

OTHER_GOV 1 OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Neoplasm Metastasis 1

Interventions

Cisplatin 44 Fluorouracil 39 Cyclophosphamide 37 Oxaliplatin 34 Capecitabine 31 Docetaxel 29 Drug Therapy 28 Gemcitabine 26 Radiotherapy 24 Paclitaxel 23 Leucovorin 20 Dexamethasone 19 Carboplatin 18 Doxorubicin 16 apatinib 15 Etoposide 15 Methotrexate 14 Cytarabine 14 Magnetic Resonance Spectroscopy 13 Epirubicin 12 Busulfan 12 Radiation 11 Bevacizumab 11 Surgical Procedures, Operative 10 Decitabine 10 venetoclax 9 camrelizumab 9 Saline Solution 9 Radiosurgery 9 Neoadjuvant Therapy 9

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03295565 2022-04-15

OSTRICh

The Netherlands Cancer Institute

Phase 2/3 Completed

Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon ⚡